Rational design based synthetic polyepitope DNA vaccine for eliciting HIV-specific CD8+ T cell responses

Molecular Immunology

Volumn 47, Issue 7-8, 2010, Pages 1507-1515

  Bazhan, S I ^a   Karpenko, L I ^a   Ilyicheva, T N ^a   Belavin, P A ^a   Seregin, S V ^a   Danilyuk, N K ^a   Antonets, D V ^a   Ilyichev, A A ^a  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

Author keywords

CD8+ T cell epitopes; CD8+ T cell responses; DNA vaccine; HIV 1; Immunogenicity; Poly CD8+ T cell epitope immunogen; Proteasome mediated processing; Ubiquitin

Indexed keywords

DNA VACCINE; EPITOPE; GAG PROTEIN; HLA A2 ANTIGEN; NEF PROTEIN; POL PROTEIN; VIRUS ENVELOPE PROTEIN; VPR PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA PURIFICATION; ENDOPLASMIC RETICULUM; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN TRANSPORT; TRANSGENE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPES, T-LYMPHOCYTE; HIV-1; HUMANS; MICE; MOLECULAR SEQUENCE DATA; VACCINES, DNA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS; VACCINIA VIRUS;

EID: 77950627264     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.01.020     Document Type: Article

References (43)

1. Alexander J., Oseroff C., Sidney J., Wentworth P., Keogh E., Hermanson G., Chisari F.V., Kubo R.T., Grey H.M., Sette A. Derivation of HLA-A11/K b transgenic mice. Functional CD8+ T cell repertoire and recognition of human A11-restricted CD8+ T cell epitopes. J. Immunol. 1997, 159:4753-4761.
2. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., Snoke K., Serra H.M., Kubo R.T., Sette A., Grey H.M. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1:751-761.
3. Andersson H.A., Barry M.A. Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol. Ther. 2004, 10:432-446.
4. Andre S., Seed B., Eberle J., Schraut W., Bultmann A., Haas L. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. Virology 1998, 72:1497-1503.
5. Bazhan S.I., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., Karpenko L.I., Nekrasova N.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Poryvaeva V.A., Aborneva I.V., Ilyichev A.A. Designing and engineering of DNA-vaccine construction encoding multiple CD8+ T cell epitopes of major HIV-1 antigens. Vaccine 2004, 22:1672-1682.
6. Cardinaud S., Bouziat R., Rohrlich P.S., Tourdot S., Weiss L., Langlade-Demoyen P., Burgevin A., Fiorentino S., van Endert P., Lemonnier F.A. Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct. AIDS 2009, 23:1945-1954.
7. Ciccarone V., Chu Y., Schifferli K., Pichet J.-P., Hawley-Nelson P., Evans K., Roy L., Bennett S. Lipofectamin 2000 reagent. Focus 1999, 21:54-55.
8. Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., Riviere Y., Danos O., Michel M.L., Kosmatopoulos K., Lemonnier F.A. Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses using HLA-A*0201 transgenic, H-2 class I KO mice. Eur. J. Immunol. 2001, 10:3064-3074.
9. Firat H., Cochet M., Rohrlich P.-S., Garcia-Pons F., Darche S., Danos O., Lemonnier F.A., Langlade-Demoyen P. Comparative analysis of the CD8+ T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int. Immunol. 2002, 14:925-934.
10. Goldberg A.L., Rock K.L. Proteolysis, proteasomes and antigen presentation. Nature 1992, 357:375-379.
11. Haeryfar S.M., DiPaolo R.J., Tscharke D.C., Bennink J.R., Yewdell J.W. Regulatory T cells suppress CD8+ T cell responses induced by direct priming and cross-priming and moderate immunodominance disparities. J. Immunol. 2005, 174:3344-3351.
12. Hanke T., Schneider J., Gilbert S.C., Hill A.V.S., McMichael A. DNA multi-CD8+ T cell epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998, 16:426-436.
13. Hanke T., Blanchard T.J., Schneider J., Ogg G.S., Tan R., Becker M., Gilbert S.C., Hill A.V.S., Smith G.L., Mcmichael A. Immunogenicity of intravenous and intramuscular administration of modified vaccinia virus Ankara-based multi-CD8+ T cell epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol. 1998, 79:83-90.
14. Hanke T., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., Hill A.V.S., Smith G.L., Mcmichael A. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime MVA boost vaccination regime. Vaccine 1998, 16:439-445.
15. Ishioka G., Fikes J., Hermanson G., Livingston B., Crimi C., Qin M., del Guercio M.-F., Oseroff C., Dahlberg C., Alexander J., Chesnut R.W., Sette A. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CD8+ T cell epitopes. J. Immunol. 1999, 162:3915-3925.
16. Karpenko L.I., Nekrasova N.A., Ilyichev A.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Zaitsev B.N., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., Bazhan S.I. Comparative analysis of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HIV-1 polyepitope CD8+ T cell-immunogen. Vaccine 2004, 22:1692-1699.
17. Kuttler C., Nussbaum A.K., Dick T.P., Rammensee H.G., Schild H., Hadeler K.P. An algorithm for the prediction of proteasomal cleavages. J. Mol. Biol. 2000, 298:417-429.
18. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 1993, 57:183-289.
19. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001, 19:4652-4660.
20. Lorin C., Delebecque F., Labrousse V., Da Silva L., Lemonnier F., Brahic M., Tangy F. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 2005, 23:4463-4472.
21. Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 1984, 49:857-864.
22. Masopust D., Vezys V., Marzo A.L., Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001, 291:2413-2417.
23. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y., Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
24. Oldstone M.B. Viral persistence. Cell 1989, 56:517-520.
25. Peters B., Bulik S., Tampe R., van Endert P.M., Holzhutter H.G. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J. Immunol. 2003, 171:1741-1749.
26. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 1998, 188:1075-1082.
27. Porgador A., Yewdell J.W., Deng Y., Bennink J.R., Germain R.N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997, 6:715-726.
28. Price D.A., Sewell A.K., Dong T., Tan R., Goulder P.J., Rowland-Jones S.L., Phillips R.E. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr. Biol. 1998, 8:355-358.
29. Princiotta M.F., Finzi D., Qian S.B., Gibbs J., Schuchmann S., Buttgereit F., Bennink J.R., Yewdell J.W. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003, 18:343-354.
30. Rammensee H.G., Falk K., Roetzschke O. MHC molecules as peptide receptors. Curr. Opin. Immunol. 1993, 5:35-44.
31. Rodriguez F., An L.L., Harkins S., Zhang J., Yokoyama M., Widera G., Fuller J.T., Kincaid C., Campbell I.L., Whitton J.L. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J. Virol. 1998, 72:5174-5181.
32. Thomson S., Elliott S.L., Sherritt M., Sproat K.W., Coupar B.E., Scalzo A.A., Forbes C.A., Ladhams A.M., Mo X.Y., Tripp R.A., Doherty P.C., Moss D.J., Suhrbier A. Recombinant polyepitope vaccines for the delivery of multiple CD8+ cytotoxic T cells epitopes. J. Immunol. 1996, 157:822-826.
33. Thomson S., Khanna R., Gardner J., Burrows S.R., Coupar B., Moss D.J., Suhrbier A. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:5845-5849.
34. Toes R.E., Nussbaum A.K., Degermann S., Schirle M., Emmerich N.P., Kraft M., Laplace C., Zwinderman A., Dick T.P., Muller J., Schonfisch B., Schmid C., Fehling H.J., Stevanovic S., Rammensee H.G., Schild H. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 2001, 194:1-12.
35. Uebel S., Wiesmuller K.H., Jung G., Tampe R. Peptide libraries in cellular immune recognition. Curr. Top. Microbiol. Immunol. 1999, 243:1-21.
36. Varshavsky A., Turner G., Du F., Xie Y. Felix Hoppe-Seyler lecture 2000. The ubiquitin system and the N-end rule pathway. Biol. Chem. 2000, 381:779-789.
37. Velders M.P., Weijzen S., Eiben G.L., Elmishad A.G., Kloetzel P.M., Higgins T., Ciccarelli R.B., Evans M., Man S., Smith L., Kast W.M. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 2001, 166:5366-5373.
38. Wagner L., Yang O.O., Garcia-Zepeda E.A., Ge Y., Kalams S.A., Walker B.D., Pasternack M.S., Luster A.D. Beta-chemokines are release from HIN-1-specific T cells granules complexed to proteoglycans. Nature 1998, 391:908-911.
39. Wentworth P.A., Vitiello A., Sidney J., Keogh E., Chesnut R.W., Grey H., Sette A. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 1996, 26:97-101.
40. Woodberry T., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., Thomson S.A., Ffrench R.A., Elliott S.L., Firat H., Lemonnier F.A., Suhrbier A. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J. Virol. 1999, 73:5320-5325.
41. Yang O.O., Kalams S.A., Trocha A., Cao H., Luster A., Johnson R.P., Walker B.D. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidences for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 1997, 71:3120-3128.
42. York I.A., Rock K.L. Antigen processing and presentation by the class I major histocompatibility complex. Ann. Rev. Immunol. 1996, 14:369-396.
43. zur Megede J., Chen M.C., Doe B., Schaefer M., Greer C.E., Selby M., Otten G.R., Barnett S.W. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 2000, 74:2628-2635.